. "GAP301/10/0883" . "http://www.isvav.cz/projectDetail.do?rowId=GAP301/10/0883"^^ . "5"^^ . "Nephrotoxicity of cisplatin \u2013 role of the Na+/K+-ATPase"@en . "5"^^ . . . "Projekt studoval v\u00FDznamn\u00FD probl\u00E9m - nefrotoxicitu cisplatiny. Auto\u0159i charakterizovali jej\u00ED interakci s Na-K ATP\u00E1zou a definovali vazebn\u00E1 m\u00EDsta na enzymu. Informace podan\u00E9 \u0159e\u0161itelem v z\u00E1v\u011Bre\u010Dn\u00E9 zpr\u00E1v\u011B jsou relevantn\u00ED. Projekt je z\u00E1kladem pro budouc\u00ED studie o prevenci nefrotoxicity. Auto\u0159i publikovali mimo jin\u00E9 5 prac\u00ED v \u010Dasopisech s IF (IF od 2,1-4,7). \u017D\u00E1dn\u00E9 nedostatky nebyly zji\u0161t\u011Bny."@cs . "cisplatin; Na+/K+-ATPase; cancerostatics; side; effects"@en . . "1"^^ . " cancerostatics" . "Cisplatin is one of the most potent chemotherapy agents used in human and veterinary medicine. It was approved for the treatment of both ovarian and testicular cancer in 1978, and it is also administered for many other types of tumors, e.g. sarcomas, small cell lung cancer or lymphomas. Unfortunately, administration of cisplatin is associated with numerous inevitable side-effects. Of these, the most clinically significant and common toxicity is nephrotoxicity. Mechanisms of this negative effect are not fully understood.In our project, we would like to test the hypothesis that it is a consequence of the Na+/K+-ATPase inhibition by cisplatin. Our preliminary experiments revealed that cisplatin is covalently bound to large cytoplasmic loop of Na+/K+-ATPase and we would like to study structural details of this interaction. Elucidation of the mechanism causing the cisplatin nephrotoxicity on the molecular level is the key step that will enable development of the protocol for efficient cancer treatment, which will not be limited by the risk of renal failure."@en . . "0"^^ . "0"^^ . . . " Na+/K+-ATPase" . . . . . . "Ciplatin nephrotoxicity is the important clinical problem. Authors studied cisplatin interaction with Na-ATPase and defined its binding sites. The information given in final report is relevant. Authors published 5 papers in journals with IF (range 2,1-4,7). No pitfalls were noticed."@en . "2014-01-30+01:00"^^ . . . . "2012-12-31+01:00"^^ . "Nefrotoxicita cisplatiny - role Na+/K+-ATP\u00E1zy" . . . "cisplatin" . . "Cisplatina je jedn\u00EDm z ne\u00FA\u010Dinn\u011Bj\u0161\u00EDch chemoterapeutik pou\u017E\u00EDvan\u00FDch v hum\u00E1nn\u00ED a veterin\u00E1rn\u00ED medic\u00EDn\u011B. V roce 1978 bylo povoleno jej\u00ED u\u017E\u00EDv\u00E1n\u00ED v l\u00E9\u010Db\u011B rakoviny vaje\u010Dn\u00EDk\u016F a varlat a v sou\u010Dasn\u00E9 dob\u011B je pou\u017E\u00EDvan\u00E1 i pro l\u00E9\u010Dbu dal\u0161\u00EDch tumor\u016F, nap\u0159. sarkom\u016F, malobun\u011B\u010Dn\u00FDch plicn\u00EDch karcinom\u016F nebo lymfom\u016F. Bohu\u017Eel administrace cisplatiny je spojena s \u0159adou ne\u017E\u00E1douc\u00EDch vedlej\u0161\u00EDch efekt\u016F, z nich\u017E nejz\u00E1va\u017En\u011Bj\u0161\u00ED a nej\u010Dast\u011Bj\u0161\u00ED je nefrotoxicita. P\u0159\u00ED\u010Diny tohoto negativn\u00EDho efektu nejsou dosud zcela objasn\u011Bny. V na\u0161em projektu bychom cht\u011Bli testovat hypot\u00E9zu, \u017Ee je zp\u016Fsoben inhibic\u00ED Na+/K+-ATP\u00E1zy cisplatinou. Na\u0161e p\u0159edb\u011B\u017En\u00E9 v\u00FDsledky uk\u00E1zaly, \u017Ee cisplatina se kovalentn\u011B v\u00E1\u017Ee na velkou cytoplazmatickou kli\u010Dku Na+/K+-ATP\u00E1zy a cht\u011Bli bychom studovat strukturn\u00ED detaily t\u00E9to interakce. Pochopen\u00ED mechanismu zp\u016Fsobuj\u00EDc\u00EDho nefrotoxicitu cisplatiny na molekul\u00E1rn\u00ED \u00FArovni je kl\u00ED\u010Dov\u00E9 pro v\u00FDvoj protokolu pro \u00FA\u010Dinnou l\u00E9\u010Dbu rakoviny, kter\u00FD nebude limitov\u00E1n rizikem selh\u00E1n\u00ED ledvin." . "2012-03-30+02:00"^^ . . "2010-01-01+01:00"^^ . " side" .